As Biden signals interest in linking drug prices with R&D costs, new study finds costs per NME are increasing

Eroom’s law (essentially the opposite of Moore’s law) holds that the development of new drugs has become slower and more expensive over time. And a new analysis, published this month in PharmacoEconomics, confirms not only that costs have gone up over the years but the difficulty in tracking how R&D has shifted.